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Background: Mesenchymal stem cells (MSCs) have been promoted as an attractive option to use as cellular
delivery vehicles to carry anti-tumor agents, owing to their ability to home into tumor sites and secrete cytokines.
Multiple isolated populations have been described as MSCs, but despite extensive in vitro characterization, little is
known about their in vivo behavior.
The aim of this study was to investigate the efficacy and efficiency of different MSC lineages derived from five
different sources (bone marrow, adipose tissue, epithelial endometrium, stroma endometrium, and amniotic
membrane), in order to assess their adequacy for cell-based anti-tumor therapies. Our study shows the crucial
importance of understanding the interaction between MSCs and tumor cells, and provides both information and a
methodological approach, which could be used to develop safer and more accurate targeted therapeutic
applications.
Methods: We first measured the in vivo migration capacity and effect on tumor growth of the different MSCs using
two imaging techniques: (i) single-photon emission computed tomography combined with computed tomography
(SPECT-CT), using the human sodium iodine symporter gene (hNIS) and (ii) magnetic resonance imaging using
superparamagnetic iron oxide. We then sought correlations between these parameters and expression of
pluripotency-related or migration-related genes.
Results: Our results show that migration of human bone marrow-derived MSCs was significantly reduced and
slower than that obtained with the other MSCs assayed and also with human induced pluripotent stem cells
(hiPSCs). The qPCR data clearly show that MSCs and hiPSCs exert a very different pluripotency pattern, which
correlates with the differences observed in their engraftment capacity and with their effects on tumor growth.
Conclusion: This study reveals differences in MSC recruitment/migration toward the tumor site and the
corresponding effects on tumor growth. Three observations stand out: 1) tracking of the stem cell is essential to
check the safety and efficacy of cell therapies; 2) the MSC lineage to be used in the cell therapy needs to be
carefully chosen to balance efficacy and safety for a particular tumor type; and 3) different pluripotency and
mobility patterns can be linked to the engraftment capacity of the MSCs, and should be checked as part of the
clinical characterization of the lineage.
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Human mesenchymal stem cells or mesenchymal stro-
mal cells (MSCs) are multipotent progenitor cells or
adult stem cells that exhibit the ability to migrate and
engraft into tumor sites when delivered systemically [1].
However, determining the most appropriate clinical ap-
plication of MSCs is hampered by the current lack of
knowledge about how these cells behave in vivo. The
precise mechanisms behind the recruitment of MSCs to
tumor sites and their migration across the endothelium
are not yet fully understood. It is probable that damaged
tissue expresses specific receptors or ligands to make pos-
sible trafficking, adhesion, and extravasation of MSCs to
the site of damage and recruitment to inflammation sites,
using a mechanism similar to leukocyte migration [2-4].
The most likely cause of specific migration is the re-
lease of chemotactic gradients from the tumors, which
may enable MSCs to home to, and modulate, the tumor
microenvironment [5,6]. Owing to these properties and
their ability to modulate the activity of immune cells,
MSCs could function as cellular delivery vehicles for
anti-tumor agents [7-9].
MSCs were first identified in the 1960s in the stromal
compartment of bone marrow [10,11], and since then,
they have been isolated from a wide variety of adult
[12-20] and fetal (both first and second trimester) tissues,
including blood, liver, bone marrow, placenta, and
umbilical cord [21-25], using similar techniques [26]. The
best-characterized source for adult human stem cells is
bone marrow, and both bone marrow-derived human
MSCs (BM-hMSCs) and adipose-derived human MSCs
(hASCs) have become attractive candidates because these
tissues are rich sources of MSCs and are easy to collect.
The other tissue-derived MSCs share a number of impor-
tant characteristics with BM-hMSCs, including expression
of cell surface marker, ability to adhere to plastic, and
capacity to differentiate into cells of mesenchymal lineage
under appropriate conditions [27]. Despite extensive
investigations, the effect of unmodified MSCs on tumor
progression remains unclear. Many studies have shown
that MSCs promote tumor progression and metastasis,
whereas others have reported that MSCs suppress tumor
growth [28]. The contradictions in these findings may be
attributable to the variability and heterogeneity in adult
stem cells from different sources, or to differences in isola-
tion methods and in vitro culture conditions. Further
development of an efficient and safe cell-based therapy will
require the in vivo tracking of engrafted MSCs to ensure
that they reach their destination. In vivo imaging techniques
provide a continuum observation rather than a single snap-
shot of conventional post-mortem histological analyses.
The aim of our work was to investigate the efficacy
and efficiency of five different MSC lineages, in order to
assess their adequacy for use as cell-based anti-tumortherapies. Our study shows the crucial importance of
understanding the interaction between MSCs and tumor
cells, and provides both information and a methodo-
logical approach, which could be used to develop safer
and more accurately targeted therapeutic applications.
The pluripotency expression pattern of MSCs was
studied and compared with that obtained in human in-
duced pluripotent stem cells (hiPSCs). Furthermore, the
effects exerted on migration-related gene expression in
tumors obtained from animals after 24 days of systemic
MSC injection were also analyzed.
Methods
Cell cultures
A human cervical cancer cell line (HeLa; Cancer Research
UK Cell Services, London Research Institute, Clare Hall
Laboratories, Herts, UK) and human PN3 fibroblasts
(kindly supplied by Dr Liu (Imperial College, London,
UK)) were used. Cells were cultured in DMEM containing
10% FBS and antibiotics (Lonza, Verviers, Belgium), at
37°C in 5% CO2.
All MSC media were supplemented with 10% FBS and
antibiotics. BM-hMSCs were obtained from Lonza and
maintained in DMEM low glucose (1.0 g/l) and hypoxic
conditions (3% O2). hASCs were obtained from Invitrogen
(UK) and cultured in MesenPro RS Basal Medium and
MesenPro RS Growth Supplement (Gibco, Paisley, UK).
Human epithelial endometrium-derived stem cells or
hEESCs (also known as endometrial epithelial stem cell
lines; ICEp) and human stroma endometrium-derived
stem cells or hESSCs (also known as endometrial stromal
stem cell lines; ICEs) were supplied by Dr Carlos Simon
from IVI (Valencia, Spain) [12,13]. Cells were maintained
in DMEM F-12 under hypoxic conditions (3% O2) and
dishes were pre-treated with 0.1% gelatin solution (Sigma-
Aldrich Chemie GmBh, Munich, Germany). Human am-
niotic membrane mesenchymal stem cells or hAMCs were
obtained from Cellular Engineering Technologies (CET),
(Coralville, IA, USA) and were maintained in DMEM high
glucose (4.5 g/l) and 10 ng/ml basic human fibroblast
growth factor (hFGFb;Gibco). Cells were used between
passages 5 to 8.
The hiPSCs (human IPSC line 2 F8) were kindly supplied
by Dr Austin Smith (University of Cambrige, UK) and cul-
tured in knockout DMEM (Gibco), 15% knockout serum
(Gibco), 1× NEAA (Lonza), 0.1 mmol/l β-mercaptoethanol
(Sigma-Aldrich), 10 ng/ml hFGFb, and antibiotics at 37°C
in 5% CO2. Cells were seeded on a PN3 feeder cell mono-
layer inactivated with mitomycin C (Sigma-Aldrich).
Flow-cytometry analysis
Characterization of MSCs was verified by flow cytome-
try. The negative surface markers used were CD45,
CD34, and HLA-DR, and the positive ones were CD90,
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markers refers only to hEESCs and hESSCs, respect-
ively). The antibodies used were CD13 FITC-conjugated
(Immunostep, Salamanca, Spain), CD34 Percp/Cy5.5-
conjugated (Becton Dickinson Co., Madrid, Spain), CD9
PE-conjugated (Millipore Corp., Billerica, MA, USA),
CD45 PerCP/Cy5.5-conjugated (Becton Dickinson), CD73
PE-conjugated (BD), CD90 PE-conjugated (Becton
Dickinson), CD105 FITC-conjugated (R&D Systems
Inc., Minneapolis, MN, USA), and HLA-DR APC-
conjugated (Immunostep). Briefly, cells were incubated
in PBS supplemented with 2% FBS and specific anti-
bodies at 4°C for 30 minutes. Then, cells were washed and
fixed in 1% paraformaldehyde (Sigma-Aldrich) before
FACS analysis (FACSAria system; Becton Dickinson).
In vitro MSC differentiation
For adipogenesis, MSCs were kept for 21 days in 1× basal
medium (STEMPRO® Adipocyte Differentiation Basal
Medium; Invitrogen Corp., Carlsbad, CA, USA), 1× supple-
ment (STEMPRO® Adipogenesis Supplement; Invitrogen)
and antibiotics. When differentiation was finished, cells
were stained with Oil Red O solution (Sigma-Aldrich). For
osteogenesis, MSCs were maintained for two weeks in
DMEM medium containing 10% FBS, 50 μg/ml ascorbic
acid, 100 nmol/l dexamethasone, and 10 mmol/l β-
glycerophosphate disodium salt hydrate (Sigma-Aldrich)
and antibiotics. Osteocyte formation was evaluated by
staining with Alizarin Red S (Sigma-Aldrich). Images were
visualized under a microscope (AE31; Motic Group Co.
Ltd, Causeway Bay, Hong Kong) equipped with a camera
(2500 Moticam; Motic Group) and Motic Imaging Plus 2
software (version 0.23).
Adenoviral vectors and infections
The hNIS gene is endogenously expressed mainly in the
thyroid and stomach, and is responsible for iodide
concentration. In cells expressing hNIS, gamma ray-
emitting radioisotopes such as 99mTc are accumulated,
and can be imaged by SPECT-CT, and thus the hNIS
gene can be used as a reporter gene [29]. The adenoviral
vector AdhNIS (also known as Ad10) used in this work
was based on adenovirus serotype 5, and the hNIS gene
is driven by the immediate-early cytomegalovirus pro-
moter. AdhNIS was constructed and amplified as pre-
viously described [30]. The amount of infective adenoviral
vector per cell (pFUs/cells) in culture media was expressed
as multiplicity of infection (MOI). Previously, adenoviral
infection efficiency was determined using adenoviral vec-
tor AdGFP testing at 100, 250, 500, and 1000 MOI, as in
our previous study [31] (data not shown). For the adeno-
viral infection with AdhNIS, viruses were diluted in
serum-free culture media to 500 MOI, added to cells, and
incubated at 37°C for 1 h. The complete medium was thenadded and cells were maintained for 24 h until used in the
in vivo experiments.
Ethics approval
All procedures were carried out under a project license
approved by the Ethics Committee for Animal Experi-
ments from the University of Zaragoza (Spain). The care
and use of animals was performed in accordance with
the Spanish Policy for Animal Protection RD1201/05.
Experimental in vivo design
Female BALB/c nu/nu mice 6–8 weeks old (Harlan UK
Ltd (Bicester, Oxfordshire, UK) and Harlan Interfauna
Iberica (Barcelona, Spain)) received subcutaneous (SC)
injections of 2 × 106 HeLa cells suspended in 200 μl PBS
for the generation of subcutaneous xenograft tumors.
When these tumors reached 50 mm3 in size, mice were
randomly divided into different groups, and intravenous
injections of MSC were performed. For MRI experi-
ments, animals were separated into six groups (n = 4/
group). Group 1 (BM-hMSCs injected); group 2 (hASCs
injected); group 3 (hAMCs injected); group 4 (hESSCs
injected); group 5 (hEESCs injected); and group 6 (con-
trol; PBS injected). For SPECT-CT experiments, animals
were separated into seven groups (n = 4/group), with
groups 1 to 5 as above, and groups 6 and 7 being
injected with hiPSCs or PBS (control), respectively.
Iron-oxide labeling and cell-viability assay
MSCs were magnetically labeled with superparamagnetic
iron oxide (SPIO; Endorem, Guerbet, France), as previ-
ously described [32]. SPIO is an oxide nanoparticle solu-
tion with a total iron content of 11.2 mg Fe/ml. Labeling
with SPIO acts by reducing the transverse relaxation
time on T2-weighted MRI scans. Cells were incubated
with the labeling medium containing 100 μg/ml iron for
24 h. After labeling, cells were washed to remove re-
sidual contrast agent.
Viability of the iron oxide-labeled MSCs was evaluated
by performing a long-term (10 days) in vitro exclusion
test with Trypan blue (Sigma-Aldrich).
MRI
Animals bearing the tumor xenograft were separated
into six groups (n = 4/group) when the tumors reached
50 mm3. MSCs were labeled with SPIO as described
above. Groups 1 to 5 received an intravenous injection
of 106 SPIO-labeled MSCs, while the control group
(group 6) received intravenous injection of PBS. Scans
were performed at 3, 10, 17, and 24 days after injection.
The MRI experiments were performed (Pharmascan sys-
tem; Bruker Medical GmBH, Germany, http://www.
bruker-biospin.com/pharmascan.html) using a 7.0-T
horizontal-bore superconducting magnet, equipped with
Table 1 Primers used for PCR
Primer Direction Sequence 5′→3′
hNIS Sense CCCATCGATGGAGGCCGTGGAGACCGG
Anti-sense CCCATCGATGTCAGAGGTTTGTCTCCTGC
GADPH Sense CCCATCGATGTCAGAGGTTTGTCTCCTGC
Anti-sense GGTCATGAGTCCTTCCACGAT
GADPH glyceraldehyde-3-phosphate dehydrogenase, hNIS human sodium
iodine symporter.
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with 90 mm inner diameter (maximum intensity 360
mT/m). All data were acquired using Paravision soft-
ware (Bruker). Anesthesia was initiated using oxygen
(1 l/min) containing 4% isofluorane, and maintained
during the experiment with 1 to 1.5% isofluorane in O2.
T2-weighted spin-echo anatomical images were ac-
quired by rapid acquisition with relaxation enhance-
ment (RARE) sequence in axial (12 slices) and sagittal (8
slices) orientations and the following parameters: TR 3000
ms, TE 60 ms, RARE factor 8, average 3, FOV 30 × 30
mm, acquisition matrix 256 × 256, corresponding to an
in-plane resolution of 117 × 117 μm2 and slice thickness
of 1.00 mm. Tumors were measured every 2 days and
tumor volume was calculated using the formula:
tumor volume = 1/2 L × S2, where L is long side and S
is short side.
Prussian blue staining and histological analysis
At day 24, the animals in the in vivo MRI experiments
were euthanized. Tumors and tissues were obtained,
fixed in formalin, and embedded in paraffin wax. Sec-
tions of 4 μm were obtained from the blocks for staining
with haematoxylin and eosin (Sigma-Aldrich). Staining
with Prussian blue (Sigma-Aldrich) was used to detect
labeled iron particles in the cells, in accordance with the
manufacturer’s instructions. The number of blue-stained
(positive) cells per high-power field (HPF) was calculated
by counting the cells in at least five HPFs per section,
with a minimum of five sections per sample examined.
SPECT-CT imaging
Animals bearing tumor xenograft were separated into
seven groups (n = 4/group) when the tumors reached
50 mm3. MSCs were infected with AdhNIS as described
above. Groups 1 to 6 received intravenous injection of
106 hNIS-labeled MSCs and the control group (group 7)
received intravenous injection of PBS. At 3, 10, 17, and
24 days post-injection, all groups received an intraven-
ous dose of 18.5 MBq of 99mTc. Anesthesia was initiated
by inhaled oxygen (1 l/min) containing 4% isofluorane,
and maintained during the experiment with 1 to 1.5%
isofluorane in O2. The mice were scanned using a nano-
SPECT-CT scanner for small animals (Bioscan, Paris,
France). A tomogram was taken, and the limits of the
scan were determined. A CT and a SPECT whole-body
scan were performed, with a time of 100 seconds per
acquisition. The images were reconstructed with the
MEDISO software (Medical Imaging Systems, Budapest,
Hungary); fusion of SPECT and CT images was carried
out using PMOD software (Biomedical Imagen Quantifi-
cation, Basel, Switzerland). Tumors were measured every
two days and tumor volume was calculated using the
formula for tumor volume given above.Quantification of radioisotope (99mTc) accumulation
was carried out using InVivoScope software (Medical
Imaging Systems). Fused SPECT/CT images were used
to draw the voxel-guided specific volume of interest
(VOI) to accurately quantify the total activity associated
with the whole tumor volume. Quantification of 99mTc
accumulation was expressed as ratio of tumor uptake to
muscle uptake.Reverse transcription-PCR
Total RNA was isolated from tumors from the in vivo
SPECT-CT experiment using a commercial kit (NucleoSpin
RNA II Kit; Macherey-Nagel GmBH, Dueren, Germany), in
accordance with the manufacturer’s instructions. Total
RNA was reverse-transcribed to cDNA (SuperScript II Re-
verse transcriptase; Invitrogen). Control reactions were
performed by omitting the reverse transcriptase. Reverse
transcription (RT)-PCR was carried out using hNIS-
specific and GAPDH-specific primers (Table 1). PCR was
performed using an automated system (Applied Biosystems
2720 Thermal Cycle System; Life Technologies, Glasgow,
UK). cDNA products were separated by electrophoresis.Real-time quantitative PCR
Pluripotency-related genes
Real-time quantitative PCR (qPCR) was performed to
analyze expression of NANOG, SOX2, OCT4, KLF4, and
REX1. To detect gene expression, MSCs and hiPSCs were
lysed directly in the culture dishes, then total RNA was
extracted and reverse transcription to cDNA was carried
out as described above. To test the quality of the cDNA,
mRNA of the housekeeping GADPH was amplified. RNA
from hiPSCs was used as pluripotency control. Reactions
were performed using a master mix (Taqman Universal
Master Mix II; Invitrogen) and a PCR system (Applied
Biosystems 7900HT Fast-Real Time PCR System; Life
Technologies) with probes (Applied Biosystems. Foster
City, CA, USA) (Table 2). Gene expression levels were
normalized against 18S rRNA. The ratio of the relative ex-
pression for each gene to 18S was calculated by the 2-ΔΔCq
formula. The hiPSC data were used as a calibrator for the
results presented (2-ΔΔCq = 100%).
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qPCR was performed to analyze expression of CXCL12
(SDF-1), CXCR4, MMP-2, CCL2 (MCP-1), and CCL5
(RANTES) (Sigma-Aldrich) (Table 3). To detect and
quantify gene expression, total RNA from tumors
consisting only of HeLa cells (control group) and tumors
consisting of HeLa cells with MSCs or hiPSCs injected
intravenously were isolated and then reverse-transcribed
to cDNA. Reactions were performed using SYBR Green
(Power SYBR Green PCR Master Mix; Life Technolo-
gies) and a real-time PCR system (Applied Biosystems
7500; Life Technologies). Reactions were performed in
duplicate from three different dilutions, and threshold
cycle values were normalized to the housekeeping gene
18S. The specificity of the products was determined by
melting curve analysis and gel electrophoresis. The ratio
of the fold difference expression for each gene to 18S
was calculated using the -ΔΔCq formula. Gene expression
levels were normalized against 18S rRNA and the ex-
pression obtained from the control group was used as a
calibrator (-ΔΔCq = 0).
Statistical analysis
Results are reported as mean ± SEM. Statistical evaluation
of data was carried out using the SPSS Statistics software
package (version 17.0; IBM SPSS, Chicago, IL, USA).
Normal distribution of the variables was analyzed by
means of the Kolmogorov-Smirnov test followed by the
Tukey HSD test, except for KLF4 and REX1 expression in
the pluripotency qPCR assays, whose distribution was
non-parametric and so analysis was performed using the
Kruskal-Wallis test. P<0.05 was considered significant.
Results
To confirm whether labeled MSCs injected systemically
into animals are able to migrate, proliferate, and engraft
into the microenvironment of tumors, two non-invasive
imaging techniques were performed in the present study:
1) SPECT-CT using hNIS as reporter gene, and 2) MRI
labeled with iron nanoparticles (SPIO).
Before performing specific studies, it was tested
whether these cells gave rise to adipocytes and osteo-
blasts when they were placed in specific differentiatingTable 2 TaqMan® gene expression assays used to amplify
the pluripotency-related genes
Gene Assay ID Amplicon size, nucleotides Dye
NANOG Hs02387400_g1 109 FAM
SOX2 Hs01053049_s1 91 FAM
OCT4 Hs00742896_s1 65 FAM
KLF4 Hs00358836_m1 110 FAM
REX1 Hs00358836_m1 102 FAM
18S 4352930E 187 FAM/MGBconditions to show their multi-lineage differentiation po-
tential (Figure 1A). In addition, it was verified that cells
were negative (≤19%) for CD45, CD34, and HLA-DR sur-
face markers, and positive (≥97%) for CD90, CD73, and
CD105, as well as CD9 and CD13 (the latter two specific
for hEESCs and hESSCs, respectively) (Figure 1B).
Cell-viability assay of SPIO-labeled MSCs
Before performing MRI scans, viability of SPIO-labeled
MSCs was determined by Trypan blue exclusion assay.
Cell-viability values, compared the control group (100%),
with 99.23 ± 3.18% in the BM-hMSC group, 101.53 ±
5.6% in the hASC group, 96.4 ± 1.75% in the hEESC
group, 100.28 ± 0.97% in the hESSC group, and 98.05 ±
6.15% in the hAMC group, thus revealing that labeling
with SPIO did not significantly affect cell viability and
proliferation.
In vivo tropism of MSCs to tumors, detected by non-
invasive imaging techniques
The ability of MSCs to migrate in vivo towards tumor
sites was first determined through MRI (Figure 2). The
study of expression of surface markers by flow cytometry
did not bring about changes in MSCs phenotype after
SPIO labeling (Figure 3A). The recruitment of SPIO-
labeled MSCs to tumors resulted in a decrease in signal
intensity (SI) and visualization of darker areas in tumor
sites. Tumors were visible as lighter areas. The changes
in SI were detected by T2-weighted images. Although
no decrease in SI was detected in control animals (data
not shown), changes in SI were seen in the different
MSCs injected from the first determination at day 3.
Images of hASCs, hEESCs, and hESSCs at day 3 showed
a higher SI decrease than hAMCs and BM-hMSCs.
These differences were more pronounced from day 10,
thus highlighting the differences in the ability of certain
cells to migrate towards tumor areas. In all groups, SI
decrease was observed first around the tumor sites and
then inside the tumors, and was much more significant
in hEESCs and hESSCs. To confirm these data, Prussian
blue staining was used to detect SPIO-labeled MSCs in
tumor sections obtained from animals scanned at day
24. Intense blue clusters were seen in tumor sections
(Figure 3B). Higher-magnification images show the
intra-cytoplasmic localization of the iron particles and
the absence of extracellular iron. The number of
Prussian blue-stained positive cells per HPF was calcu-
lated in tumor sections (Figure 3C). There were signifi-
cantly more Prussian blue-stained positive cells in tumor
sections of hESSCs (66.1 ± 3.72) compared with BM-
hMSCs (23.6 ± 3.30).
A second in vivo imaging technique, SPECT-CT, was
performed. Selected tumor transverse sections of SPECT-
CT scans are shown in Figure 4A. The images obtained by
Table 3 Primers used to amplify the migration-related genes
Primer GenBank accession number Direction Sequence (5′→ 3′)
CXCR4 NM_003467 Sense TGGCCGACCTCCTCTTTGT
Anti-sense AGTTTGCCACGGCATCAACT
SDF-1 (CXCL12) NM_000609 Sense CCAACGTCAAGCATCTCAAAATT
Anti-sense AGCCGGGCTCAATCTGAAG
RANTES (CCL5) NM_002985 Sense TGCCCACATCAAGGAGTATTTCTA
Anti-sense GCACACACTTGGCGGTTCT
MCP-1 (CCL2) NM_002990 Sense GCGTGGTGTTGCTAACCTTCA
Anti-sense GGCTCTTCATTGGCTCAGCTT
MMP-2 NM_004530 Sense TTTTGATGACGATGAGCTATGGA
Anti-sense CCATCGGCGTTCCCATACT
18S NR_003286 Sense CGGCTACCACATCCAAGGAA
Anti-sense GCTGGAATTACCGCGGCT
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nal being blue and the strongest red. In whole-body scans
of control mice, an endogenous hNIS expression signal
was present in the thyroid gland, salivary glands, stomach,
and bladder. Accumulation of 99mTc, reflecting hNIS ex-
pression, was detected at tumor sites in animals that re-
ceived the hNIS-labeled MSC injection. No signal was
detected in tumor sites of the control animals (data not
shown). Because MRI assays indicated differences in signal
levels at first determinations, hiPSCs were included in the
SPECT-CT assays to study whether pluripotency status
can affect migration ability.
hMSCs did not exert any signal at day 3, and their
highest signal was found at day 10 (1.92 ± 0.72), after
which it decreased until day 24 (1.07 ± 0.12). In hiPSCs
and in the other hMSCs assayed, various levels of signal
were detected from day 3, with hASCs presenting the
lowest signal (1.44 ± 0.69) and hESSCs the highest (2.01 ±
0.18). Figure 4B shows the differences at day 3. The
detected signals increased for the following determina-
tions, with MSCs reaching their maximum level at day 17,
when hESSCs also had their highest values (3.84 ± 0.41),
whereas the highest signal for hiPSCs (6.73 ± 1.23)
occurred at day 24. For MSCs, the detected signals de-
creased after 24 days, with the highest values being for
hAMCs (3.07 ± 0.29) and hESSCs (2.89 ± 0.69), and the
lowest for hASCs (2.46 ± 0.68) and hEESCs (2.52 ±
0.72). The tumor:muscle uptake ratio showed the diffe-
rences between the migration ability of MSCs and
hiPSCs (Figure 4C).
To confirm MSC and hiPSC engraftment, hNIS ex-
pression was performed by RT-PCR (Figure 5). At day
24, the animals were euthanized, and RNA was extracted
from tumors as described above. hNIS expression was
detected in all groups with differences of intensity. These
differences may be due to the differences seen in thedistribution of MSCs and hiPSCs in tumors and also to
episomal hNIS expression mediated by adenovirus.
Findings suggest that MSCs and hiPSCs have the ability
to migrate to and engraft into tumor sites. In SPIO-
labeled MSCs and in hNIS-labeled MSCs and hiPSCs,
the signal was maintained for up to 24 days after injec-
tion, depending on the cell type. BM-hMSCs showed the
lowest migration ability, being detected in tumor sites at
day 10, whereas hiPSCs showed the highest capacity,
with increased signals until day 24. The other MSC types
were detected from the first determination (day 3) and
the signal was stronger until the final determination (day
24), thus revealing that more cells can reach tumor areas
and remain there for longer periods.
Pluripotency analysis
To investigate whether pluripotency may be involved in
the migration ability of MSCs, analysis of the expression
of pluripotency-related genes was performed (Figure 6).
qPCR analysis showed that the expression of the genes
studied was significantly lower in MSCs compared with
the control sample, hiPSCs (taken as 100%). Moreover,
differences were found in the expression levels between
the MSCs. NANOG, and KLF4 expression was higher in
hEESCs and hESSCs than in the other MSCs. There
were no significant differences in SOX2 expression be-
tween the different MSCs, and OCT4 levels were very
similar for MSCs as well, except for hAMCs in which
expression was significantly lower (0.96%). REX1 was
expressed only in hESSCs and BM-hMSCs (<0.01%).
These results clearly show that although all cell types in
the study may be considered MSCs, they exert a very
different pluripotency pattern, and are also different
from hiPSCs, which may be related to the differences in
their engraftment capacity in addition to their effects on
tumors.
Figure 1 Characterization of MSCs. (A) Multi-lineage differentiation potential in vitro to give rise to osteoblasts and adipocytes. Morphologic
changes and expression of specific markers for each tissue are shown. (B) Specific surface markers expression (%) detected by flow cytometry.
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When tumors reached a size of 50 mm3, approximately
10 days after HeLa injection, the animals receivedintravenous injection of MSCs or hiPSCs (Figure 7).
Tumor size was measured until the end of the experi-
ments (34 days after HeLa injection and 24 days after
Figure 2 In vivo xenograft imaging of mice using a magnetic resonance labeling (MRI) scanner. Scans were performed at 3, 10, 17, and 24
days after intravenous injection of super-paramagnetic iron oxide (SPIO)-labeled mesenchymal stem cells (MSCs). Tumors were visible as lighter
areas in transverse sections. The recruitment of SPIO-labeled MSCs to tumors resulted in decrease of signal intensity (SI) and the visualization of
darker areas in tumor sites. The same animals are represented over the entire period.
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clearly different depending on the type of MSCs or
hiPSCs injected. Until day 13, the tumors of all the
groups showed a similar growth pattern. However,
differences between groups became clear at day 20, and
were maintained until day 34. At this point, control tu-
mors consisting of HeLa cells had an average size of
110 ± 26.8 mm3, whereas tumors composed of HeLa
cells and MSCs had faster growth. Tumors resulting
from the hEESC, hESSC, hASC, and hAMC injections
reached a similar average size between 346 and 315
mm3, significantly larger than the control tumors except
for those resulting from BM-hMSC injections (174.9 ±
17.7 mm3). Tumors composed of HeLa cells and hiPSCs
had the fastest growth rates and reached an average size
of 594.8 mm3, significantly larger than those in the othergroups. The significantly higher growth of HeLa cells and
MSC or hiPSC tumors compared with the control group in-
dicatesmigration and engraftment of these cells into tumors.
Migration analysis
To compare the expression of migration-related genes in
tumors consisting only of HeLa cells (control group) and
tumors consisting of HeLa cells and MSCs or hiPSCs,
mRNAs encoding CXCR4, CXCL12, CCL5, CCL2, and
MMP-2 were quantified by qPCR (Figure 8).
In general, expression levels of migration-related genes
in tumors obtained from HeLa cells and MSC or hiPSC
injection were significantly lower than those of control
samples. CXCL12 expression was significantly decreased
in all groups, with the smallest decrease seen in BM-
hMSCs (−4.4 ± 0.04-times), and the largest in hASCs,
Figure 3 (See legend on next page.)
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Figure 3 Super-paramagnetic iron oxide (SPIO) labeling analysis. (A) Phenotypic analysis after SPIO labeling. Prussian blue staining in tumor
sections obtained from animals scanned by MRI at day 24. (B) Images show intense blue clusters in tumor sections. (B1) SPIO-labeled bone
marrow-derived human mesenchymal stem cells (BM-hMSCs); (B2) SPIO-labeled human adipose-derived stem cell (hASCs); (B3) SPIO-labeled
human epithelial endometrium-derived stem cell (hEESCs); (B4) SPIO-labeled human stromal endometrium-derived stem cells (hESSCs); (B5) SPIO-
labeled human amniotic membrane mesenchymal stem cells (hAMCs; (B6) control cells. Original magnification: (B1-B5) ×20; (B6) ×10. (C) number
of Prussian blue-stained positive cells per high-power field (HPF) in tumor sections.
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For CCL5, expression levels were significantly decreased
in tumors obtained from BM-hMSCs (−1.69 ± 0.25-
fold), hEESCs (−2.31 ± 0.08-fold), and hESSCs (−2.58 ±
0.08-fold), but were significantly increased in hAMCs
(1.73 ± 0.07-fold) and hiPSCs (0.85 ± 0.1-fold). In the
hASC group, the expression level was similar to that of
the control samples (−0.25 ± 0.12-fold). CCL2 and
CXCR4 expression levels were significantly decreased in
tumors resulting from MSC injection, with the hAMC
group showing the lowest decrease (−1.05 ± 0.07-fold
and −0.98 ± 0.12-fold, respectively), whereas the hiPSC
group had significantly increased expression levels
(5.53 ± 0.18-fold and 0.60 ± 0.33-fold, respectively). Fi-
nally, MMP-2 expression was significantly decreased in
tumors composed of HeLa cells and BM-hMSCs (−6.28 ±
0.22-fold), hASCs (−6.99 ± 0.12-fold), hEESCs (−5.62 ±
0.13-fold), and hAMCs (−3.09 ± 0.06-fold) but was signifi-
cantly increased in hESSCs (2.28 ± 0.07-fold) and hiPSCs
(6.48 ± 0.14-fold). These findings highlight, once again,
the differences between MSCs and hiPSCs. These diffe-
rences may be responsible for the different migration
patterns and probably play a role in the effects on the
microenvironment in tumors.
Discussion
MSCs have been promoted as an attractive option for
cellular delivery vehicles to carry anti-tumor agents,
owing to their ability to home into tumor sites and se-
crete cytokines [28,33,34]. Previous studies have shown
that systemic delivery of MSCs does not result in en-
graftment into healthy organs, but that they do migrate
in various in vivo tumor models, although this mechanism
has not yet been fully elucidated [35-42]. Additionally,
MSCs can also counteract inflammation by suppressing
host immune responses [28] and by secreting anti-
inflammatory cytokines [43].
The ability of MSCs and hiPSCs to migrate into tumor
sites after systemic injection into mice is confirmed in
the present study. HeLa-based subcutaneous xenograft
tumors showed extensive MSC engraftment, and BM-
hMSC migration was significantly lower and slower than
that obtained by the other MSCs and hiPSCs. All cell
types were detected by MRI in a similar way to recent
results obtained with MSCs by other groups [43]. Signals
were obtained from the first (day 3) until the final (day 24)imaging determination, except in BM-hMSCs, which
highlights the capacity of these cells to persist in tumor
sites. These results and the differences between BM-
hMSCs and the other cell types were confirmed by iron-
particle staining and the detection of hNIS in tumor
samples. Using SPECT-CT images and hNIS expression,
another study has shown BM-hMSC migration towards
a breast-cancer model [44]. In contrast to our observa-
tions, hNIS expression in that study was detected in
tumors from day 3 after MSC injection, which may be
attributed to the differences between donors, tumor
models, and the size of the pre-established tumor.
To clarify whether pluripotency plays a role in MSC
migration to tumors, a pluripotency marker panel was
analyzed. These studies revealed diminished expression
of SOX2, NANOG, OCT4, KLF4, and REX1 compared
with the control sample (hiPSCs). hEESCs and hESSCs,
which displayed the highest signals in the imaging
techniques, also had significant expression of KLF4,
NANOG, and REX1 with respect to the other MSCs, al-
though it was much lower than that shown by hiPSCs.
These differences in pluripotency patterns may influence
the differences in migration and engraftment of MSCs
and hiPSCs.
Tumor growth confirmed the ability of MSCs to migrate
into tumors, and the significant differences between BM-
hMSCs, the other MSCs, and hiPSCs. In a previous PC3
prostate xenograft model [45], intra-tumoral injection of
hASCs also induced larger tumors compared with the
control group, although the differences between control
and hASC-induced tumors were smaller at the final time
point (<2-fold vs. 3-fold in ours). These differences may
be attributed to the different tumor model used and the
different procedures for hASC injection. However, there
are also studies reporting inhibitory effects on tumor
growth in an in vivo tumor model following MSC injec-
tion, using different approaches from ours [46,47]. The
dose of MSCs delivered and the timing of injection have
been highlighted as determining factors in the promotion
or inhibition of tumor growth [28].
Although the mechanisms behind homing are not yet
fully understood, the most likely cause of preferential
migration is the release of chemotactic gradients from
tumors. MSCs have a wide range of chemokine and
cytokine receptors on their cell surface, which respond
functionally to their ligands in vitro, whereas in vivo,
Figure 4 (See legend on next page.)
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Figure 4 In vivo xenograft imaging of mice using a nano-single-photon emission computed tomography/X-ray computed tomography
(nano-SPECT-CT) scanner. Scans were performed at 3, 10, 17, and 24 days after intravenous injection of human sodium iodine symporter
(hNIS)-labeled mesenchymal stem cells (MSCs) and human induced pluripotent stem cells (hiPSCs). An intravenous dose of 18.5 MBq of 99mTc
was administered before the acquisitions. The same animals are represented over the entire period. hNIS expression is indicated by red crosses in
transverse sections. Scans were performed after intravenous injection of hNIS-labeled MSCs or hiPSCs. (A) Images at days 3, 10, 17 and 24;
(B) images at day 3; (C): 99mTc tumor/muscle uptake ratio by hNIS-labeled MSCs or hiPSCs from days 3 to 24.
Belmar-Lopez et al. BMC Medicine 2013, 11:139 Page 12 of 16
http://www.biomedcentral.com/1741-7015/11/139their modification implies changes in migration beha-
vior [48-52].
Some authors have shwon that MSCs secrete a large
panel of chemokines such as CXCL12, CCL2, and
CCL5, which implies activation of the MAPK, FAK, and
STAT signaling pathways, and the induction of bio-
logical responses [48,49]. Moreover, tumors produce a
wide range of chemokines and cytokines, which may act
as ligands for MSC receptors [35,53]. Of the different
pairs of receptor/ligand described as responsible for mi-
gration, the CXCL12/CXCR4 pair should be highlighted.
This has been studied in numerous works, both in vitro
and in vivo, and using different tumor models or MSCs
sources [35,49-51,54-59]. Loss of expression in MSC´s
receptors [48] implies a loss in cell-migration ability, in-
dicating the great importance of these axes in MSC
migration.
The relationship between homing and the inflamma-
tory state has been assessed, and studies have been
conducted in which BM-hMSCs were pre-treated with
factors involved on inflammation (such as tumor necro-
sis factor, MMP2, CXCL12 and CCL5) [49]. But some
studies were contradictory [35,50], which it could be due
to the variation in donors or cell-culture conditions
(confluence, hypoxia, and passages) [60].
Our results show that, in general, when MSCs engraft
into tumors, migration-related gene expression is de-
creased (whereas hiPSCs exert an increase) except for
the CXCL12/CXCR4 axis, causing a significant depletion
in the expression of both markers when MSCs are
present. The exceptions were hiPSCs, in which CXCR4Figure 5 Detection of human sodium iodine symporter (hNIS) expres
tumors of animals scanned by single-photon emission computed tomograexpression increased. The reason for this may be that
CXCL12 expression is also linked to more immature cell
fractions, with higher expression in less committed
stages of differentiation, that is, in cells closer to the em-
bryonic state [61]. With regard to hiPSCs, this study and
another previous work [62] are the first to highlight their
in vivo migration ability to and long-term engraftment
into tissue damage areas.
Besides the release of chemotactic gradients from the
tumors, other explanations for MSCs migration could be
the hypoxic conditions produced by tumor cells, which
may cause MSCs to increase the expression of migratory
signals [63], and thus confer the ability to cross the
biological barriers [59]. However, in our study, a direct
correlation between the migration patterns and the ab-
sence of oxygen does not seem to exist (data not shown).
Finally, a recent dialogue mediated by exosomes be-
tween MSCs from the bone marrow and tumoral cells in
patients with melanoma [64] has been shown. The de-
gree of exosome release by the various MSCs could de-
termine the migratory differences between those cells,
depending both on their area of origin and also on their
exosome targeting.
Conclusion
This study clarifies the in vivo capacity of different types
of MSCs and hiPSCs to migrate and engraft into a
tumor model. The results reveal that the adult stem cells
assayed were able to enter tumor sites and remain there,
at least until the end of the experiments. Their different
pluripotency pattern may also play a role in thesion by reverse transcription (RT)-PCR. RNA was extracted from
phy/X-ray computed tomography (SPECT-CT) at day 24.
Figure 6 Pluripotency-related gene expression by quantitative (q)PCR. Gene expression levels were normalized against 18S rRNA. The ratio
of the relative expression for each gene to 18S was calculated by using the 2-ΔΔCq formula. hiPSC data were used as a calibrator for the results
presented (100%). (A) OCT4 and KLF4; (B) NANOG, SOX2 and REX1.
Figure 7 Effect on xenograft tumor growth. When tumors
reached a size of 50 mm3, the animals received an intravenous
injection of mesenchymal stem cells (MSCs; arrow). The size of the
tumors was measured until the end of the experiments (34 days
after the HeLa injection and 24 days after the MSC injection).
Figure 8 Migration-related gene expression by quantitative
(PCR). CXCR4, CXCL12, CCL5, CCL2, and MMP-2 expression in
tumors (control group) was compared with expression in tumors
consisting of HeLa cells and mesenchymal stem cells (MSCs) or of
HeLa cells and human induced pluripotent stem cells (hiPSCs)
(analyzed 24 days after stem cell injection). The ratio of the fold
difference expression for each gene to 18S was calculated by using
the -ΔΔCq formula. Expression obtained from the control group was
used as a calibrator.
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http://www.biomedcentral.com/1741-7015/11/139differences between these cell types, in which higher
imaging signals but also higher tumor growth were
obtained in those with highest expression of pluripotency
genes. Moreover, MSCs and hiPSCs also exerted different
migration-related gene profiles in tumors, which could be
attributed to the anti-inflammatory effect exerted by
MSCs, thereby diminishing expression of the migration
marker. Our promising data support the importance of
MSCs as therapeutic gene carriers in anti-tumor treat-
ments, and highlight the importance of choosing the most
suitable lineage for specific tumor lesion. Further under-
standing of the role of MSCs in tumors and the promising
possibility to use them as therapeutic gene vehicles may
lead to potentially fruitful treatment approaches.
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